Clinical Study
Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer
Table 1
Details of patients.
| | OC | JC | GC | value |
| | Number | 18 | 32 | 35 | | | Median age (years) | 60 | 66 | 72 | 0.012 | | Gender Mββ:βF (%) | 18β:β0 (100β:β0) | 27β:β5 (84β:β16) | 19β:β16 (54β:β46) | <0.0001 | | Surgery (%) | | | | | | βTTO | 7 (39) | 9 (28) | β | | | βTHO | 11 (61) | 13 (41) | β | | | βTG | β | 10 (31) | 9 (26) | | | βSTG | β | β | 26 (74) | | | HER2+ (%) | 2 (11) | 14 (44) | 4 (11) | 0.003 | | pTNM (%) | | | | | | βI and II | 10 (56) | 12 (37) | 20 (57) | 0.062 | | βIII and IV | 8 (44) | 20 (63) | 15 (43) |
|
|
OC: Oesophageal adenocarcinoma; JC: junctional adenocarcinoma; GC: gastric adenocarcinoma; TTO: transthoracic oesophagectomy; THO: transhiatal oesophagectomy; TG: total gastrectomy; STG: subtotal gastrectomy.
|
